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Adherence and persistence
Curkendall et al., evaluated adherence and persistence in patients receiving DPP-4 inhibitors, GLP-1 agonists, SU and TZD showing that:
• • Patients receiving DPP-4 inhibitors were more persistent compared with GLP-1 agonists, SU and TZD (OR reported graphically).
• Compared with DPP-4, the probability of discontinuation was 71% higher for those taking GLP-1 analogs, 63% higher for those taking SU, and 55% higher for those taking TZD.
• Adherence may be better with DPP-4 inhibitors due to a better tolerability than with the other medications.
Rathmann et al., evaluated treatment persistence to DPP-4 inhibitors and sulfonylureas showing that:
• DPP-4 inhibitors were associated with a lower risk of treatment discontinuation (non-persistence: 39%) compared with SU (49%) [Hazard Ratio=0.74; 95% CI=0.71-0.76].
• In this study, previous hypoglycemia was related to a future risk of hypoglycemic events. The authors suggested that this fact could contribute to non-persistence.
Patient satisfaction
The results of the study conducted by Genovese et al., showed that:
• Combination of DPP-4 inhibitors and metformin increased patient's satisfaction a 30% compared with metformin monotherapy.
• The proportion of patients 'very satisfied' with treatment increased from baseline by 44.7%; patients who perceived themselves as hyperglycemia-free increased a 37.9% from baseline (from 6.3% to 26.9%) and those who perceived as hypoglycemia-free increased a 15.2% (from 29.8% to 40.9%).
• The authors supported these figures with clinical data: improvement of HbA1c in 54% of patients and stabilization of HbA1c in 41%.
Treatment preferences
DiBonaventura et al., study showed that:
• Most patients preferred the DPP-4 inhibitor profile over the GLP-1 agonist profile (wave 1: 81.9% vs. 18.1%; wave 2: 84.4% vs. 15.6%; p<0.001).
• Most patients preferred to take first the DPP-4 inhibitor profile over GLP-1 agonist profile, if they could switch later (wave 1: 82.8% vs. 17.2%; wave 2: 85.0% vs. 15.0%; p<0.001).
• Most patients believed they could take the DPP-4 inhibitor profile longer than the GLP-1 agonist profile (wave 1: 83.4% vs. 16.6%; wave 2: 86.5% vs. 13.5%; p<0.001).
• In the Spanish population (n=188), the proportion of patients preferring DPP-4 inhibitors was even higher (90.4% vs. 9.6%; p<0.001).
Conclusions
• PROs in DPP-4 inhibitors are poorly described in the literature.
• Nevertheless, DPP-4 inhibitors are preferred as first option and are associated with higher persistence and satisfaction levels, mainly due to higher perception of glycemic control and lower hypoglycemia risk.
Background
• The individualization of treatment is key in type 2 diabetes mellitus (T2DM) patients according to guidelines 1 .
• Besides efficacy and safety outcomes, patient preferences, treatment adherence and health-related quality of life (HRQoL) should be taken into account in treatment choice 1 .
• Recent systematic reviews including dipeptidyl peptidase-4 (DPP-4) inhibitors have explored clinical or economic outcomes, but patientreported outcomes (PROs) have not been considered.
Objective
• To synthesize the available information on the therapeutic value of DPP-4 inhibitors for T2DM treatment considering published data on PROs.
Materials and methods
• A systematic review was performed on Spanish (IBECS, MEDES) and international (PubMed, ISI WOK, Scopus, Cochrane Library) databases.
• Observational studies regarding HRQoL, adherence, persistence, satisfaction or preferences assessed in T2DM patients receiving DPP-4 inhibitors. The selected studies were published in English or Spanish until June 2013.
Results
• Of 1,713 references identified, 13 full-text articles were evaluated for eligibility and 4 publications met inclusion criteria (Figure 1 ).
• The characteristics of the selected publications are described in 
